/
/
Abordagem de processamento paralelo multi-alvo para Gene-a-estrutura Determinação da polimerase da gripe PB2 Subunidade
This content is Free Access.
1Protein Crystallization Lab,Emerald Bio, 2Molecular Biology Lab,Emerald Bio, 3Scientific Sales Representative,Emerald Bio, 4Group Leader II,Emerald Bio, 5Group Leader I,Emerald Bio, 6Chair of Advisory Board,Emerald Bio, 7Director of Multi-Target Services,Emerald Bio, 8Senior Project Leader,Emerald Bio, 9Project Leader II & SSGCID Site Manager,Emerald Bio
Capítulos
- 00:05Título
- 02:20Construct Design
- 04:07Polymerase Incomplete Primer Extension (PIPE) Cloning
- 06:14Expression Optimization
- 08:21Large Scale Fermentation
- 09:40Protein Purification – Cell Lysis
- 10:54Protein Purification – Affinity Chromatography
- 13:04Protein Purification – Affinity Tag Cleavage
- 14:47Protein Purification – Size-exclusion Chromatography (SEC)
- 15:42Protein Crystallization
- 17:03Crystal Harvesting
- 18:15Crystal Screening/Data Collection
- 19:27Results: 3D Structure Determination of Influenza Virus PB2
- 21:05Conclusion
Concepção de fármacos com base Estrutura desempenha um papel importante no desenvolvimento de medicamentos. Prosseguindo alvos múltiplos em paralelo aumenta a chance de sucesso para a descoberta de chumbo. O seguinte artigo destaca como o Seattle Center Structural Genomics para Doenças Infecciosas utiliza uma abordagem multi-alvo para determinação da influenza A subunidade PB2 gene-to-estrutura.
Tags
Multi-targetParallel ProcessingGene-to-structure DeterminationInfluenza Polymerase PB2 SubunitPandemic OutbreaksInfluenza Virus InfectionPoint MutationsVirulence FactorAntiviral Drug TargetStructural Genomics ProgramNational Institute Of Allergy And Infectious Disease (NIAID)Emerald BioSeattle Structural Genomics Center For Infectious Disease (SSGCID)Three-dimensional Protein StructuresNIAID Category A-C PathogensStructure-based Drug DesignDrug Development
